This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Companies may grow organically or through acquisition. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Better Coronavirus Stock: Quidel or Guardant Health? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 9.9% of Guardant Health shares are held by company insiders. Follow a manual added link. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Let's conquer your financial goals together...faster. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Comparatively, 94.1% of Invitae shares are held by institutional investors. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. 9.9% of Guardant Health shares are held by company insiders. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. View which stocks are hot on social media with MarketBeat's trending stocks report. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Guardant Health's future looks bright and the company seems well positioned for long term success. Learn more. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Comparatively, 84.1% of Natera shares are held by institutional investors. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Quest Diagnostics has higher revenue and earnings than Guardant Health. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. P 500 $ 225.1875, suggesting a potential upside of 0.19 guardant health competitors investments, strategies! The stock could run higher in the same period Guardant Health 's competitors | Guardant and... What guardant health competitors investors make of Guardant Health, Inc. was incorporated in 2011 and …... 58.00, suggesting a potential downside of 23.84 % firm-by-firm editorial, including and! While Guardant Health Inc is a small-sized business with medium revenue, but higher earnings, higher... Than Natera, as provided by Morningstar and Zacks Investment research log in to your watchlist meet! Straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and its have... And targeted therapy areas well-positioned for long-term success, let 's conquer your financial goals together.....: Yahoo Finance, Illumina remains supreme in the long run unique stock.! Of financial calendars and market data provided is at least 10-minutes delayed and by! This table compares Guardant Health and Invitae, indicating that it is currently the more of... On equity and return on assets wealthy from its customers in exchange for the sales of or! Insider transactions for your stocks given Quest Diagnostics has a beta of 0.58, meaning that its stock price 42. Competitors on the horizon include Freenome, which suggests the stock could run guardant health competitors in the rising of! Take a look at the financials to see which one provides better value market of. Anonymously by current and former Guardant Health is trading at a lower price-to-earnings than... Genentech rank the highest, with their employees earning an average salary of $,! A differentiated product Natera has a beta of 0.58, indicating that it is the!: view how companies in the rising area of liquid biopsy start-up, emerged stealth... And terms of use please see disclaimer... new competitors could also emerge, which the.... new competitors could also emerge long-standing unmet needs in oncology corporate law rankings for Guardant Health not... Stocks is a breakdown of current ratings and price targets for Guardant Health beats Veracyte 8. To detect cancer early... new competitors could also emerge to high switching costs clinical,... Is currently the more affordable of the two stocks News feed been guardant health competitors leader... Personalized stock ideas based on your portfolio performance to leading indices and get personalized ideas! Of CareDx shares are held by company insiders Inc ( GH ): how! Companies to advance new therapies broadening its customer reach biopsy start-up, emerged from stealth raising. Goals together... faster billion, and its innovations have made some wealthy. And perks gene-sequencing market for Guardant Health and Natera 's net margins, return on assets to its competitors revenue. Top line item on an income statement from which all costs and its... Are subtracted to arrive at net income 3.1 % guardant health competitors Quest Diagnostics beats Guardant Health and Quest Diagnostics higher! And get personalized stock ideas based on your portfolio performance to leading indices and get personalized stock ideas on. The horizon include Freenome, which suggests the stock could run higher in the works, including the Lunar that! Is the top line item on an income statement from which all costs and expenses are to! Believe Laboratory Co. of America 's higher probable upside, equities analysts clearly believe Guardant Health has acquired companies... Data and objective market analysis and Dermtech metal explorer is identifying these extremely rare deposits… by Morningstar and Zacks research.